To observe the clinical effect of Dengzhan Shengmai capsule in the treatment of lower extremity arteriosclerosis obliterans.

60 patients were randomly divided into a control group and a treatment group, 30 for each group. The control group was treated with conventional western medicine alprostadil, while the treatment group was treated with oral Dengzhan Shengmai capsule on the basis of alprostadil, 2 capsules each time, three times a day. The two groups were treated for 14 days as a cycle and 4 cycles as a treatment course. The treatment effects were compared between these two groups.

The total effective rate of the treatment group was 96.7%, and that of the control group 80.0% (P<0.05). After the treatment, the ABI and TBI increased significantly in both groups (all P<0.05), and the changes of ABI and TBI in the treatment group were more significant than those in the control group (both P<0.05). After the treatment, the internal diameters of the posterior femoral artery, the posterior tibial artery and the dorsal pedal artery of the two groups increased significantly (all P<0.05). In addition, the hemorheology and endothelium of the two groups were significantly improved after treatment, and were better in the treatment group (all P<0.05).

Dengzhan Shengmai capsule is effective in treating lower extremity arteriosclerosis obliterans, through improving microcirculation, inhibiting thrombosis, and regulating the release of vascular endothelial factors.

Dengzhan Shengmai capsule; Lower extremity arteriosclerosis obliterans; Efficacy